常规细胞角蛋白免疫组化在宫颈癌低体积病灶检测中的价值
该回顾性研究纳入2008至2020年UMC Utrecht的234例FIGO IA-IIA1期宫颈癌患者,评估前哨淋巴结常规pancytokeratin免疫组化(IHC)的临床增益与成本。IHC使低体积病灶患者从11例(5.3%)增至19例(9.1%)(p=0.04),仅1.4%(95%CI 0.3%-4.3%)患者辅助治疗因此调整,额外成本约€94,775。作者认为鉴于高成本,常规IHC的成本效益存疑。
要点
- IHC使低体积病灶检出率从5.3%升至9.1%(p=0.04)。
- 仅1.4%(95%CI 0.3%-4.3%)患者辅助治疗因IHC调整。
- 3791张IHC染色切片额外成本约€94,775,成本效益存疑。
核心结论
- 常规IHC较单纯H&E步进切片使宫颈癌前哨淋巴结低体积病灶检出率提高近4%,约1%患者治疗策略受影响,但鉴于高成本,常规IHC的成本效益存疑。
研究设计与样本
- 回顾性纳入2008至2020年UMC Utrecht所有接受前哨淋巴结手术的FIGO IA-IIA1期宫颈癌患者,病理数据来自荷兰病理登记库(PALGA)。
- 共纳入234例患者,病理学家发现516份手术切除前哨淋巴结标本中的630枚前哨淋巴结,其中211例患者的579枚前哨淋巴结常规行IHC。
主要发现
- IHC检出H&E未发现的3例微转移和5例孤立肿瘤细胞(ITC)。
- IHC使低体积病灶患者从11例(5.3%)增至19例(9.1%)(p=0.04)。
- 为检出上述病灶,共3791张切片行IHC染色,估计额外成本€94,775。
- 1.4%(95%CI 0.3%-4.3%)患者的辅助治疗因常规IHC而调整。
临床怎么用
- 作者认为常规IHC的成本效益存疑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In cervical cancer, sentinel lymph nodes (SLNs) are processed according to the pathological ultrastaging protocol. According to current guidelines, immunohistochemistry with pancytokeratin antibodies is performed in addition to step sectioning with hematoxylin and eosin (H&E), aiding the detection of low volume disease (micrometastasis and isolated tumor cells (ITC)). We studied the added clinical value, and costs, of routine immunohistochemistry (IHC). METHODS: We retrospectively included all FIGO stage IA-IIA1 cervical cancer patients who had undergone SLN procedures at UMC Utrecht from 2008 to 2020. Pathological data were derived from the Dutch Pathology Registry (PALGA) including SLN tumor status and number of slides stained with IHC. RESULTS: In total 234 cervical cancer patients were included. In the 516 surgically resected SLN specimens, 630 SLNs were discovered by the pathologist. Hereof, 579 SLNs from 211 patients were routinely processed with IHC. IHC identified three patients with micrometastasis and five patients with ITC undetected with H&E staining. Thereby, IHC significantly increased the number of patients with low volume disease from 11 (5.3%) to 19 patients (9.1%) (p = 0.04). To achieve this, 3791 slides were stained with IHC at an estimated additional cost of €94,775. In 1.4% (95% CI 0.3%-4.3%) of patients routine use of IHC adjusted the adjuvant treatment. CONCLUSIONS: Routine use of IHC increases detection of low volume disease in cervical cancer SLNs compared to step sectioning with H&E alone by nearly 4%, with an impact on therapeutic strategy-decisions in about 1% of patients. In view of the high associated costs, cost-effectiveness of routine IHC is questionable.
引用
- Baeten IGT, Hoogendam JP, Jonges GN, et al. Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer. Gynecol Oncol. 2022. PMID: 35219527. doi:10.1016/j.ygyno.2022.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。